CanSino to Add Shanghai Star Board IPO to Hong Kong Listing
publication date: Oct 14, 2019
CanSino Biologics, a Tianjin vaccine company, filed to IPO on the Shanghai Star Board, six months after it completed a $161 million initial offering in Hong Kong. In the first day of trading following the Hong Kong IPO, CanSino rose 58%, and it remains 72% above the IPO price six months later. The company said it would issue 24.8 million shares in the Shanghai offering, but it has not set its pricing goals yet. CanSino has an approved Ebola vaccine and six vaccine candidates in clinical trials or CTA stage, along with 6 pre-clinical vaccine candidates. More details....
Stock Symbol: (HK: 6185)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.